UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Annals of oncology, 2018-09, Vol.29 (9), p.1895-1902

2018

Volltextzugriff (PDF)

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors

Annals of oncology, 2015-09, Vol.26 (9), p.1824-1829

2015

Volltextzugriff (PDF)

Ocular toxicities of MEK inhibitors and other targeted therapies

Annals of oncology, 2016-06, Vol.27 (6), p.998-1005

2016

Volltextzugriff (PDF)

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

Gynecologic oncology, 2017-02, Vol.144 (2), p.250-255

2017

Volltextzugriff (PDF)

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients

Gynecologic oncology, 2019-05, Vol.153 (2), p.304-311

2019

Volltextzugriff (PDF)

342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors

European journal of cancer (1990), 2015-09, Vol.51, p.S68-S68

2015

Volltextzugriff (PDF)

508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041)

European journal of cancer (1990), 2014-11, Vol.50, p.165-166

2014

Volltextzugriff (PDF)

Venous thromboembolic events stratified by number of risk factors in patients with metastatic germ cell tumours undergoing first-line chemotherapy

European urology open science (Online), 2020-07, Vol.19, p.e398-e399

2020

Volltextzugriff (PDF)

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Annals of oncology, 2019-03, Vol.30 (3), p.365-373

2019

Volltextzugriff (PDF)

Leveraging big data of immune checkpoint blockade response identifies novel potential targets

Annals of oncology, 2022-12, Vol.33 (12), p.1304-1317

2022

Volltextzugriff (PDF)

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Annals of oncology, 2022-04, Vol.33 (4), p.416-425

2022

Volltextzugriff (PDF)

Transfer of Follow-up Care to Family Physicians for Early-stage Breast Cancer

Clinical oncology (Royal College of Radiologists (Great Britain)), 2007-04, Vol.19 (3), p.172-176

2007

Volltextzugriff (PDF)

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

European journal of cancer (1990), 2019-01, Vol.107, p.1-7

2019

Volltextzugriff (PDF)

2033MO The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study

Annals of oncology, 2023-10, Vol.34, p.S1079-S1079

2023

Volltextzugriff (PDF)

S5 Aiming at the target: In the crosshairs or the crossfire?

Breast (Edinburgh), 2009, Vol.18, p.S2-S3

2009

Volltextzugriff (PDF)

1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients

Annals of oncology, 2022-09, Vol.33, p.S1303-S1304

2022

Volltextzugriff (PDF)

375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors

Annals of oncology, 2023-10, Vol.34, p.S333-S333

2023

Volltextzugriff (PDF)

1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

Annals of oncology, 2023-10, Vol.34, p.S625-S626

2023

Volltextzugriff (PDF)

310P Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay

Annals of oncology, 2023-10, Vol.34, p.S308-S308

2023

Volltextzugriff (PDF)

731MO A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors

Annals of oncology, 2022-09, Vol.33, p.S877

2022

Volltextzugriff (PDF)

490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)

Annals of oncology, 2022-09, Vol.33, p.S764-S765

2022

Volltextzugriff (PDF)

Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study

Clinical oncology (Royal College of Radiologists (Great Britain)), 2020-10, Vol.32 (10), p.e188-e193

2020

Volltextzugriff (PDF)

Neurotoxicity Among Survivors of Testicular Cancer: A Population-based Study

Clinical oncology (Royal College of Radiologists (Great Britain)), 2019-09, Vol.31 (9), p.653-658

2019

Volltextzugriff (PDF)

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors††This study was presented in part at the 50th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-Jun 3, 2014

Annals of oncology, 2015-09, Vol.26 (9), p.1824-1829

2015

Volltextzugriff (PDF)

336P PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)

Annals of oncology, 2020-09, Vol.31, p.S381-S382

2020

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(21)
Life Sciences & Biomedicine
(18)
Oncology
(16)
Humans
(10)
Female
(6)
Adult
(5)
Hematology, Oncology And Palliative Medicine
(5)
Neoplasms - Drug Therapy
(5)
Middle Aged
(4)
Neoplasms - Pathology
(4)
Targeted Therapies
(4)
Aged
(3)
Animals
(3)
Breast Cancer
(3)
Immune Checkpoint Inhibitors
(3)
Male
(3)
Precision Medicine
(3)
Technology
(3)
Adolescent
(2)
Adverse Event
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors

Ocular toxicities of MEK inhibitors and other targeted therapies

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients

342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors

508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041)

Venous thromboembolic events stratified by number of risk factors in patients with metastatic germ cell tumours undergoing first-line chemotherapy

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Leveraging big data of immune checkpoint blockade response identifies novel potential targets

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Transfer of Follow-up Care to Family Physicians for Early-stage Breast Cancer

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

2033MO The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study

S5 Aiming at the target: In the crosshairs or the crossfire?

1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients

375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors

1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

310P Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay

731MO A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors

490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)

Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study

Neurotoxicity Among Survivors of Testicular Cancer: A Population-based Study

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors††This study was presented in part at the 50th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-Jun 3, 2014

336P PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)

Suchergebnisse filtern